Entrada Therapeutics, Inc.
TRDA
$10.07
$0.222.23%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.61M | 1.95M | 20.56M | 37.40M | 19.57M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.61M | 1.95M | 20.56M | 37.40M | 19.57M |
| Cost of Revenue | 38.36M | 37.88M | 32.07M | 33.41M | 31.26M |
| Gross Profit | -36.75M | -35.93M | -11.52M | 3.99M | -11.69M |
| SG&A Expenses | 10.30M | 10.92M | 10.27M | 9.86M | 9.97M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 48.67M | 48.80M | 42.35M | 43.27M | 41.23M |
| Operating Income | -47.05M | -46.85M | -21.79M | -5.87M | -21.66M |
| Income Before Tax | -43.48M | -42.93M | -17.35M | -739.00K | -15.89M |
| Income Tax Expenses | 654.00K | 178.00K | -- | -1.87M | -1.86M |
| Earnings from Continuing Operations | -44.13M | -43.10M | -17.35M | 1.13M | -14.03M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -44.13M | -43.10M | -17.35M | 1.13M | -14.03M |
| EBIT | -47.05M | -46.85M | -21.79M | -5.87M | -21.66M |
| EBITDA | -45.82M | -45.82M | -20.84M | -4.88M | -20.72M |
| EPS Basic | -1.06 | -1.04 | -0.42 | 0.03 | -0.35 |
| Normalized Basic EPS | -0.66 | -0.65 | -0.26 | -0.01 | -0.24 |
| EPS Diluted | -1.06 | -1.04 | -0.42 | 0.02 | -0.35 |
| Normalized Diluted EPS | -0.66 | -0.65 | -0.26 | -0.01 | -0.24 |
| Average Basic Shares Outstanding | 41.46M | 41.34M | 41.07M | 40.84M | 40.63M |
| Average Diluted Shares Outstanding | 41.46M | 41.34M | 41.07M | 43.05M | 40.63M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |